Title: SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes

Immunosuppressive therapy (IST) yields durable hematologic improvement (HI) in a subset of patients with lower risk myelodysplastic syndrome (MDS). We investigated the impact of somatic gene mutations on response to IST in lower risk MDS. Among 40 patients evaluated by NGS, the presence of an SF3B1 mutation (MT) was significantly associated with IST nonresponse (1 of 9 SF3B1 MT, 11% vs. 21 of 31 wild type (WT), 68%; p=0.002). In multivariable analysis, combination with cyclosporine, no prior hypomethylating and absence of SF3B1 MT were predictive of response

Source: Clinical Lymphoma, Myeloma and Leukemia - January 8, 2020 Category: Hematology Authors: Qing Zhang, Mintallah Haider, Najla H. Al Ali, Jeffrey E. Lancet, Pearlie K. Epling-Burnette, Alan F. List, Eric Padron, Rami S. Komrokji Tags: Original Study Source Type: research